Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
作者
Ilka Hoof,Marianne Witten,Thomas Stranzl,Stéphanie Brand,Mohamed H. Shamji,Eric Donn Bateman,Eugene R. Bleecker,Peter Sejer Andersen
出处
期刊:The European respiratory journal [European Respiratory Society] 日期:2021-09-05卷期号:: PA877-PA877
标识
DOI:10.1183/13993003.congress-2021.pa877
摘要
Many individuals with asthma have an underlying allergy, and house dust mites (HDMs) are a common trigger. Biomarkers of the type 2 (Th2) immune response are associated with severity of allergic asthma. The aim of this study was to investigate the association between baseline values of Th2 biomarkers and efficacy of sublingual allergy immunotherapy (SLIT)-tablet treatment. MITRA (Clinicaltrialsregister.eu 2010-018621-19) was a phase III, randomized, double-blind, placebo-controlled trial of HDM SLIT-tablets in 834 adults with HDM allergic asthma. A post-hoc analysis of the MITRA study population was performed to evaluate the association between baseline levels of the Th2 inflammatory biomarkers blood eosinophils, eosinophil cationic protein (ECP), total IgE and tryptase and the primary study endpoint (time to first moderate/severe asthma exacerbation). High levels of Th2/allergic biomarkers were associated with increased risk of asthma exacerbations in the placebo group (blood eosinophils: HR=1.7, 95% CI [1.07, 2.71]; ECP: HR=1.76 [1.1, 2.82]; tryptase: HR=1.76 [1.08, 2.86]), but HDM SLIT-tablet treatment reduced this elevated risk in the Th2 biomarker ‘high’ subgroup (blood eosinophils: HR=0.5 [0.30, 0.85]; ECP: HR=0.5 [0.29, 0.87]; tryptase: HR=0.45 [0.25, 0.80]), where ‘high’ was defined as values above the 80th percentile per individual biomarker. Our results indicate that AIT with HDM SLIT-tablets is effective in HDM-sensitized asthma patients with high levels of Th2 inflammatory biomarkers.